What is Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (301096.SZ) StockRank?

MoatMap's StockRank for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) is 21/100, with a Sell signal. This is a composite score combining Quality (33), Value (27), and Momentum (49) factor ranks across MoatMap's 20,000+ stock universe.

Does Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. have an economic moat?

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. a buy, hold, or sell?

MoatMap's current signal for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. in?

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

301096.SZ

SELL

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. · Healthcare · China · $961M · Avg Vol: $28M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-2.0%

D/E

0.4x

Dividend %

—

COMPANY DESCRIPTION

Hangzhou Bio-Sincerity Pharma-Tech is a contract research organization (CRO) providing comprehensive clinical research services for pharmaceutical and biotechnology companies. The company's competitive moat is its expertise in clinical trial management, regulatory affairs, and bioanalysis, particularly for generic drugs and innovative biologics. It is a fast-growing, specialized service provider in China's expanding pharmaceutical R&D outsourcing market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	89.5M	149.9M	118.1M	99.9M	3.7%	104.5M
EPS	0.27	0.37	-0.07	-0.12	39.4%	-0.07
Shares	108.2M	108.9M	109.2M	109.2M	+1.0%	109.2M
Debt	1.3M	54.6M	104.9M	128.6M	362.2%	148.8M
Equity	365.6M	395.3M	379.9M	366.6M	0.1%	—
Op CF	38.2M	13.3M	-28.8M	-22.8M	-65.1%	-13.5M
Inv CF	-101.8M	-113.0M	-68.4M	-17.8M	—	—
Fin CF	-54.0M	36.0M	43.9M	20.6M	—	—

Loading 1Y...

PRICE (1Y)-21.5%

SMA 50SMA 200

$7.47

RSI (14)

44.8

52W High

$11.37

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-2.5%41.5

ROE

-2.0%42.3

GP/Assets

7.8%22.6

Op. Margin

7.4%60.0

FCF/Assets

-4.9%33.5

Piotroski

25.7

Int. Cover

-3.3x29.7

D/E Ratio

0.40x37.3

Current Ratio

1.87x35.6

Value

P/E (TTM)

—N/A

EV/EBITDA

51.4x10.8

P/FCF

—N/A

P/B

2.2x55.7

P/S

7.8x31.8

Div Yield

—N/A

Momentum

52W High %

66%44.1

RS 6M

-15%52.9

SMA 50/200

1.05x74.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$961M

P/E (Forward)

—

Gross Margin

40.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301096.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
301096.SZ	Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.(you)	$961M	21	SELL
600666.SS	Aurora Optoelectronics Co.,Ltd.	$1.7B	25	SELL
300006.SZ	Chongqing Lummy Pharmaceutical Co., Ltd.	$698M	33	SELL
7630.HK	IMPACT THERAP-B	$1.3B	8	STRONG SELL
2630.HK	Vigonvita Life Sciences Co., Ltd.	$1.3B	3	STRONG SELL
002019.SZ	Yifan Pharmaceutical Co., Ltd.	$1.7B	38	HOLD
600771.SS	GuangYuYuan Chinese Herbal Medicine Co., Ltd.	$916M	48	HOLD
301507.SZ	Hangzhou Minsheng Healthcare Co., Ltd.	$633M	44	HOLD
688710.SS	Shanghai InnoStar Bio-tech Co., Ltd.	$1.3B	62	HOLD
300357.SZ	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	$1.6B	61	HOLD

Peer medians: ROE 4.7% · P/E 28.4x · Gross margin 52.5%

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) — Stock Score Summary

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) has a MoatMap StockRank of 21/100 based on Quality (33/100), Value (27/100), and Momentum (49/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$7.47
Market Cap	$961M
Price/Book	2.20
Return on Equity	-2.0%
Return on Invested Capital	-2.5%
Debt/Equity	40.38
Gross Margin	40.7%
Operating Margin	7.4%
Revenue Growth	24.6%
Free Cash Flow	$-27M

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates in the Drug Manufacturers - General industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.’s (301096.SZ) StockRank?: MoatMap’s StockRank for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) is 21/100, with a Sell signal. It is a composite of Quality (33), Value (27), and Momentum (49) factor ranks across MoatMap’s 20,000+ stock universe.
Does Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. have an economic moat?: Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. a buy, hold, or sell?: MoatMap’s current signal for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. in?: Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (China).